US Stocks
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc

Finch Therapeutics Group Inc (FNCH)








Key Stats

Today Low/High
11.9 / 12.54
52 Week Low/High
$11.56 / $22.5
Market Cap

Company Details

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.
Finch Therapeutics Group Inc

Discover more

Frequently Asked Questions

What is Finch Therapeutics Group Inc (FNCH) share price today?

Can Indians buy Finch Therapeutics Group Inc (FNCH) shares?

How can I buy Finch Therapeutics Group Inc (FNCH) shares from India?

Can Fractional shares of Finch Therapeutics Group Inc (FNCH) be purchased?

What are the documents required to start investing in Finch Therapeutics Group Inc (FNCH) stocks?

We are a SEBI registered investement advisor